What Happened?
Shares of genomics company Illumina (NASDAQ: ILMN) fell 3.3% in the afternoon session after an analyst at Barclays maintained a cautious "Underweight" rating on the company.
Although the price target was slightly increased to $95 from $90, the maintained "Underweight" status suggested the analyst believed the stock would likely underperform the broader market. This view seemed to outweigh positive news released the same day about Illumina partnering with pharmaceutical companies to develop new cancer diagnostics. The decline also followed a strong gain during the previous trading session, which occurred after the company announced the launch of its new BioInsight business focused on using artificial intelligence for drug discovery.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Illumina? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Illumina’s shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 1 day ago when the stock gained 6.6% on the news that the company announced the launch of BioInsight, a new business unit designed to accelerate drug discovery using artificial intelligence.
The new venture aims to help researchers and pharmaceutical companies analyze and interpret vast amounts of complex biological data, known as multiomic data. By combining its strengths in genetic sequencing, software, and AI, Illumina's BioInsight unit will provide solutions to identify new drug targets, understand biological pathways, and uncover disease mechanisms. This strategic move is intended to meet growing industry demand for data-driven insights, supporting the company's long-term growth by expanding its role in the life sciences and healthcare sectors.
Illumina is down 24.5% since the beginning of the year, and at $98.87 per share, it is trading 36.3% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of Illumina’s shares 5 years ago would now be looking at an investment worth $320.55.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
